Dariohealth CORP. 8-K Filing
Ticker: DRIO · Form: 8-K · Filed: Nov 10, 2025 · CIK: 1533998
| Field | Detail |
|---|---|
| Company | Dariohealth CORP. (DRIO) |
| Form Type | 8-K |
| Filed Date | Nov 10, 2025 |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $10,000,000 m, $11,000,000, $2,500,000 b, $150,000 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Dariohealth CORP. (ticker: DRIO) to the SEC on Nov 10, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.0001 (registered Common Stock, par value $0.0001 per share DRIO The Nasdaq Capital M); $10,000,000 m (the existing minimum cash covenant to a $10,000,000 minimum consolidated unencumbered liquid); $11,000,000 (ing requirement when liquidity is below $11,000,000 (subject to a certain EBITDA exception)); $2,500,000 b (ification that an additional funding of $2,500,000 by the Lenders is uncommitted and at the); $150,000 (crease in the exit fee by an additional $150,000 (which may be waived if a change-of-con).
How long is this filing?
Dariohealth CORP.'s 8-K filing is 3 pages with approximately 834 words. Estimated reading time is 3 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 834 words · 3 min read · ~3 pages · Grade level 12.3 · Accepted 2025-11-10 16:17:15
Key Financial Figures
- $0.0001 — registered Common Stock, par value $0.0001 per share DRIO The Nasdaq Capital M
- $10,000,000 m — the existing minimum cash covenant to a $10,000,000 minimum consolidated unencumbered liquid
- $11,000,000 — ing requirement when liquidity is below $11,000,000 (subject to a certain EBITDA exception)
- $2,500,000 b — ification that an additional funding of $2,500,000 by the Lenders is uncommitted and at the
- $150,000 — crease in the exit fee by an additional $150,000 (which may be waived if a change-of-con
- $15.3495 — $ 16.556 (post reverse stock split) to $15.3495 per share as well as to reduce the conv
- $2,500,000 — to reduce the conversion price of up to $2,500,000 of the Callodine Loan Facility from $19
- $19.866 — 000 of the Callodine Loan Facility from $19.866 (post reverse stock split) to $15.3495.
Filing Documents
- tm2530754d1_8k.htm (8-K) — 30KB
- tm2530754d1_ex4-1.htm (EX-4.1) — 160KB
- tm2530754d1_ex10-1.htm (EX-10.1) — 618KB
- 0001104659-25-109166.txt ( ) — 1128KB
- drio-20251105.xsd (EX-101.SCH) — 3KB
- drio-20251105_lab.xml (EX-101.LAB) — 33KB
- drio-20251105_pre.xml (EX-101.PRE) — 22KB
- tm2530754d1_8k_htm.xml (XML) — 4KB
01
Item 1.01 E ntry into a Material Definitive Agreement. Amendment to Credit Agreement On November 5, 2025, DarioHealth Corp. (the "Company") entered into an amendment (the "Credit Agreement Amendment") to its existing credit agreement (the "Callodine Loan Facility"), with the financial institutions party thereto from time to time as lenders and Callodine Commercial Finance, LLC (in its capacity as agent for all lenders, and collectively with other lenders, "Lenders" and each a "Lender"). Among other things, the Credit Agreement Amendment provides for (i) a reset of financial covenants and waives financial-covenant testing for the second and third quarters of 2025; (ii) the replacement of the existing minimum cash covenant to a $10,000,000 minimum consolidated unencumbered liquid assets covenant; (iii) a monthly 13-week cash-flow reporting requirement when liquidity is below $11,000,000 (subject to a certain EBITDA exception); (iv) a clarification that an additional funding of $2,500,000 by the Lenders is uncommitted and at the Lenders' discretion; and (v) an increase in the exit fee by an additional $150,000 (which may be waived if a change-of-control prepayment fee is triggered). The Company paid an amendment fee of $150,000 to Callodine Commercial Finance, LLC. In connection with the Credit Agreement Amendment, on November 5, 2025, the Company also amended and restated the warrants (the "Warrant Amendment") issued to the Lenders upon the execution of the Callodine Loan Facility, to reduce the exercise price of the Lender Warrants from $ 16.556 (post reverse stock split) to $15.3495 per share as well as to reduce the conversion price of up to $2,500,000 of the Callodine Loan Facility from $19.866 (post reverse stock split) to $15.3495. The foregoing description of the terms of the Credit Agreement Amendment and the Warrant Amendment are not intended to be complete and are qualified in their entirety by reference to the Credit Agreement Amendment and the Warr
03
Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth in Item 1.01 is incorporated by reference into this Item 2.03.
02
Item 3.02 Unregistered Sales of Equity Securities. The response to this item is included in Item 1.01, Entry into a Material Definitive Agreement, and is incorporated herein in its entirety.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits 4.1^ Form of Amended and Restated Warrant. 10.1^ Credit Agreement Amendment, dated November 5, 2025, by and among the Company, as borrower, Callodine Commercial Finance, LLC, as agent and lender, and the financial institutions party thereto from time to time as lenders . 104 Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101) ^ Certain identified information in the exhibit has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to DarioHealth Corp. if publicly disclosed
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: November 10, 2025 DARIOHEALTH CORP. By: /s/ Chen Franco-Yehuda Name: Chen Franco-Yehuda Title: Chief Financial Officer, Treasurer and Secretary